Cargando…

Coronary atherosclerosis and chemotherapy: From bench to bedside

Cardiovascular disease, particularly coronary artery disease, is the leading cause of death in humans worldwide. Coronary heart disease caused by chemotherapy affects the prognosis and survival of patients with tumors. The most effective chemotherapeutic drugs for cancer include proteasome inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Fanghui, Zhu, Xinxin, Liu, Yao, Sun, Yue, Zhang, Ying, Cheng, Dechun, Wang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892653/
https://www.ncbi.nlm.nih.gov/pubmed/36742069
http://dx.doi.org/10.3389/fcvm.2023.1118002
_version_ 1784881367341858816
author Zhou, Fanghui
Zhu, Xinxin
Liu, Yao
Sun, Yue
Zhang, Ying
Cheng, Dechun
Wang, Wei
author_facet Zhou, Fanghui
Zhu, Xinxin
Liu, Yao
Sun, Yue
Zhang, Ying
Cheng, Dechun
Wang, Wei
author_sort Zhou, Fanghui
collection PubMed
description Cardiovascular disease, particularly coronary artery disease, is the leading cause of death in humans worldwide. Coronary heart disease caused by chemotherapy affects the prognosis and survival of patients with tumors. The most effective chemotherapeutic drugs for cancer include proteasome inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, 5-fluorouracil, and anthracyclines. Animal models and clinical trials have consistently shown that chemotherapy is closely associated with coronary events and can cause serious adverse cardiovascular events. Adverse cardiovascular events after chemotherapy can affect the clinical outcome, treatment, and prognosis of patients with tumors. In recent years, with the development of new chemotherapeutic drugs, new discoveries have been made about the effects of drugs used for chemotherapy on cardiovascular disease and its related mechanisms, such as inflammation. This review article summarizes the effects of chemotherapeutic drugs on coronary artery disease and its related mechanisms to guide efforts in reducing cardiovascular adverse events during tumor chemotherapy, preventing the development of coronary heart disease, and designing new prevention and treatment strategies for cardiotoxicity caused by clinical tumor chemotherapy.
format Online
Article
Text
id pubmed-9892653
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98926532023-02-03 Coronary atherosclerosis and chemotherapy: From bench to bedside Zhou, Fanghui Zhu, Xinxin Liu, Yao Sun, Yue Zhang, Ying Cheng, Dechun Wang, Wei Front Cardiovasc Med Cardiovascular Medicine Cardiovascular disease, particularly coronary artery disease, is the leading cause of death in humans worldwide. Coronary heart disease caused by chemotherapy affects the prognosis and survival of patients with tumors. The most effective chemotherapeutic drugs for cancer include proteasome inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, 5-fluorouracil, and anthracyclines. Animal models and clinical trials have consistently shown that chemotherapy is closely associated with coronary events and can cause serious adverse cardiovascular events. Adverse cardiovascular events after chemotherapy can affect the clinical outcome, treatment, and prognosis of patients with tumors. In recent years, with the development of new chemotherapeutic drugs, new discoveries have been made about the effects of drugs used for chemotherapy on cardiovascular disease and its related mechanisms, such as inflammation. This review article summarizes the effects of chemotherapeutic drugs on coronary artery disease and its related mechanisms to guide efforts in reducing cardiovascular adverse events during tumor chemotherapy, preventing the development of coronary heart disease, and designing new prevention and treatment strategies for cardiotoxicity caused by clinical tumor chemotherapy. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9892653/ /pubmed/36742069 http://dx.doi.org/10.3389/fcvm.2023.1118002 Text en Copyright © 2023 Zhou, Zhu, Liu, Sun, Zhang, Cheng and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Zhou, Fanghui
Zhu, Xinxin
Liu, Yao
Sun, Yue
Zhang, Ying
Cheng, Dechun
Wang, Wei
Coronary atherosclerosis and chemotherapy: From bench to bedside
title Coronary atherosclerosis and chemotherapy: From bench to bedside
title_full Coronary atherosclerosis and chemotherapy: From bench to bedside
title_fullStr Coronary atherosclerosis and chemotherapy: From bench to bedside
title_full_unstemmed Coronary atherosclerosis and chemotherapy: From bench to bedside
title_short Coronary atherosclerosis and chemotherapy: From bench to bedside
title_sort coronary atherosclerosis and chemotherapy: from bench to bedside
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892653/
https://www.ncbi.nlm.nih.gov/pubmed/36742069
http://dx.doi.org/10.3389/fcvm.2023.1118002
work_keys_str_mv AT zhoufanghui coronaryatherosclerosisandchemotherapyfrombenchtobedside
AT zhuxinxin coronaryatherosclerosisandchemotherapyfrombenchtobedside
AT liuyao coronaryatherosclerosisandchemotherapyfrombenchtobedside
AT sunyue coronaryatherosclerosisandchemotherapyfrombenchtobedside
AT zhangying coronaryatherosclerosisandchemotherapyfrombenchtobedside
AT chengdechun coronaryatherosclerosisandchemotherapyfrombenchtobedside
AT wangwei coronaryatherosclerosisandchemotherapyfrombenchtobedside